Share

CLINICAL TRIAL SEARCH RESULTS

NEW SEARCH
 Number: P2C 8317 Principal Investigator: Adkins, Douglas
Title: Phase I/II trial of Cediranib alone or Cediranib and Lenalidomide in iodine 131-refractory differentiated thyroid cancer
Description: The uprpose of this study is to learn about the side effects and determine the best dose of cediranib maleate when given with or without lenalidomide and to see how well they work in treating patients with thyroid cancer....MORE
___________________________________________________________________________________________________
 Number: 201308046 Principal Investigator: Adkins, Douglas
Title: A Randomised, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib (CAPRELSA™) 300 mg in Patients with Papillary or Poorly Differentiated Thyroid Cancer That Is Either Locally Advanced or Metastatic Who Are Refractory or Unsuitable for Radioiodine (RAI) Therapy
Description: The purpose of this study is to investigate if vandetanib can help keep thyroid cancer from growing, or progressing. This study will also explore which patients respond best to vandetanib, how vandetanib works, and how vandetanib is tolerated in patients with thyroid cancer. This study will also me...MORE
___________________________________________________________________________________________________
 Number: 201108327 Principal Investigator: Wang-Gillam, Andrea
Title: Phase I Study of Erlotinib and Temsirolimus in Resistant Solid Malignancies
Description: The purpose of this study is to determine the maximum tolerated dose and side effects of the combination of two drugs, temsirolimus and erlotinib, used to treat solid tumor cancers. Temsirolimus is approved by the Food and Drug Administration (FDA) for treatment of renal cancer and is considered inv...MORE
___________________________________________________________________________________________________
 Number: 201107068 Principal Investigator: Lockhart, A. Craig
Title: Phase I Safety and Pharmacokinetic Study of XRP6258 (Cabazitaxel) In Advanced Solid Tumor Patients with Varying Degrees of Hepatic Impairment
Description: The purpose of this study is to determine if Cabazitaxel is a safe treatment for patients with advanced cancers of different types who also have different levels of liver dysfunction. The highest safe dose of cabazitaxel (the maximum tolerated dose, or MTD) that can be given to patients with your le...MORE
___________________________________________________________________________________________________